Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 19, 2013, Pages 7844-7849

  Su, Tung Hung ^a,b   Liu, Chen Hua ^a,b   Liu, Chun Jen ^a,b   Chen, Chi Ling ^a   Ting, Te Tien ^c   Tseng, Tai Chung ^a,d   Chen, Pei Jer ^a,b   Kao, Jia Horng ^a,b   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; MICRORNA 122; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84983719318     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306138110     Document Type: Article

References (42)

1. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345(1): 41-52.
2. Hadziyannis SJ, et al.; PEGASYS International Study Group (2004) Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5): 346-355.
3. Yu ML, et al. (2007) A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56(4): 553-559.
4. Liu CH, et al. (2008) Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial. Clin Infect Dis 47(10): 1260-1269.
5. Poordad F, et al.; SPRINT-2 Investigators (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13): 1195-1206.
6. Jacobson IM, et al.; ADVANCE Study Team (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25): 2405-2416.
7. McCaughan GW, et al.; Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party (2007) Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 22(5): 615-633.
8. Cullen BR (2006) Viruses and microRNAs. Nat Genet 38(suppl):S25-S30.
9. Lagos-Quintana M, et al. (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12(9): 735-739.
10. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309(5740): 1577-1581.
11. Jopling CL (2008) Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 36(Pt 6): 1220-1223.
12. Jangra RK, Yi M, Lemon SM (2010) Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 84(13): 6615-6625.
13. Pedersen IM, et al. (2007) Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449(7164): 919-922.
14. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W (2009) Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15(1): 31-33.
15. Lanford RE, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962): 198-201.
16. Arroyo JD, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108(12): 5003-5008.
17. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39(16): 7223-7233.
18. Mitchell PS, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30): 10513-10518.
19. Ng EK, et al. (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 58(10): 1375-1381.
20. Zhang Y, et al. (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56(12): 1830-1838.
21. Xu J, et al. (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50(2): 136-142.
22. Wang K, et al. (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106(11): 4402-4407.
23. Bihrer V, et al. (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106(9): 1663-1669.
24. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating micro- RNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 6(8):e23937.
25. Morita K, et al. (2011) Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 31(4): 474-484.
26. Urban TJ, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52(6): 1888-1896.
27. Kau A, Vermehren J, Sarrazin C (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49(4): 634-651.
28. Ramcharran D, et al.; Virahep-C Study Group (2010) Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52(3): 854-863.
29. Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38(3): 639-644.
30. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J (2011) MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci USA 108(12): 4991-4996.
31. Tanaka Y, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10): 1105-1109.
32. Ge D, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262): 399-401.
33. Thomas DL, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265): 798-801.
34. Suppiah V, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon- alpha and ribavirin therapy. Nat Genet 41(10): 1100-1104.
35. Sarasin-Filipowicz M, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105(19): 7034-7039.
36. Honda M, et al.; Hokuriku Liver Study Group (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2): 499-509.
37. Lange CM, Zeuzem S (2011) IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 55(3): 692-701.
38. Hao J, et al. (2013) IFN-alpha-induced miR-122 inhibition negatively affects the anti- HBV efficiency of IFN-alpha. J Virol 87(1): 137-147.
39. Hsu SH, et al. (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122(8): 2871-2883.
40. Hunter MP, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3(11):e3694.
41. Bedossa P, Poynard T; The METAVIR Cooperative Study Group (1996) An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24(2): 289-293.
42. Knodell RG, et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1(5): 431-435.